On November 4, BeiGene announced that the US Food and Drug Administration has accepted the new marketing license application for Baiyuze® combined with rituximab for priority review and approval, and is intended for use in adult first-time patients with mantle cell lymphoma. This application is based on the results of a critical MANGROVE phase 3 clinical study. The data shows that compared to standard immunochemotherapy regimens, this chemotherapy-free treatment plan is expected to significantly reduce patients' risk of disease progression or death.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.